Relevant bibliographies by topics / Thromboembolism

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Thromboembolism'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Thromboembolism.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Thromboembolism"

DÜZ, Özge Arıcı, Oktay OLMUŞÇELİK, Ali İhsan GEMİCİ, and Özlem SAATÇİ SANCAKTEPE. "Evaluation of pai-1 polymorphisms in central and peripheral thromboembolies." Journal of Experimental and Clinical Medicine 38, no. 2 (March 14, 2021): 167–71. http://dx.doi.org/10.52142/omujecm.38.2.20.

Full text

Abstract:

Thromboembolism is a clinical finding that occurs due to thrombus; formed in the vascular system and has various etiological factors. It can be classified as central and peripheral thromboembolism. Our objective in this study is to explore genetic risk factors in central and peripheral thromboembolism and reveal the differences. 342 thromboembolism patients were retrospectively included to the study between January 2016 and December 2019. Demographic characteristics, risk factors for thromboembolism and genetic mutations in central and peripheral thromboembolism groups were overviewed. The genetic mutations evaluated in patients were Factor V Leiden G1691A, Factor V HR1299R, Factor II (Prothrombin) G20210A, MTHFR (Methylenetetrahydrofolate reductase) C677T, MTHFR A1298C, PAI 4G/5G. Within the scope of the study, genetic analyzes of 106 patients were reached and included in the study. Seventy-two central thromboembolism (69.8%), 34 (31.2%) peripheral thromboembolisms were detected. Sixty-three of the central thromboembolisms were from arterial and nine were from venous origin. There was no significant difference between age, gender and risk factors of central thromboembolism and peripheral thromboembolism patients (p˃0.05), but smoking was more common in central thromboembolism patients (p: 0.041). 4G/5G polymorphism was observed more frequently in patients with central thromboembolism (p: 0.039). Thromboembolism is a multifactorial disease, PAI-1 4G/5G polymorphism is a medium risk factor for thromboembolism. We conclude that PAI-1 4G/5G polymorphism is more frequent in central thromboembolism than peripheral thromboembolism and its evaluation can give more information about the thromboembolic risk analyze.

APA, Harvard, Vancouver, ISO, and other styles

Thomas, Sarah, Diana Braswell, and Corinne Stephenson. "Massive Pulmonary and Coronary Artery Thromboembolism in the Setting of Undetected Patent Foramen Ovale." Blood 126, no. 23 (December 3, 2015): 4718. http://dx.doi.org/10.1182/blood.v126.23.4718.4718.

Full text

Abstract:

Abstract Invasive surgery brings with it a unique set of post-surgical risks that are directly dependent on various factors including the specific surgical approach used, pre-existing comorbidities and features such as gender and age. Pulmonary thromboembolism is one of the most feared complications following surgery, and diagnosis and treatment of this entity is a challenging task for the clinician. Here we describe a case of massive pulmonary thromboembolism and associated coronary artery thromboemboli status post spinal fusion surgery in a 68 year-old man with an undetected patent foramen ovale (PFO). Although the decedent was managed clinically with proper deep venous thrombosis prophylaxis protocols and physical rehabilitation, he went into cardiorespiratory arrest after experiencing acute oxygen desaturation and newly detected right bundle branch block. PFO can be incidentally found in 25% of the adult population. Several clinical syndromes including stroke, migraine headaches and obstructive sleep apnea have been associated in patients with PFO, the last two from which the decedent suffered. The pathology of this unique case of massive pulmonary thromboembolism resulting in coronary artery thromboemboli in the setting of an undetected PFO is discussed. The discovery of PFO in patients prior to surgery, if detected early, may improve post-surgical outcomes. Figure 1. Massive pulmonary artery thromboembolism in situ, gross examination. Figure 1. Massive pulmonary artery thromboembolism in situ, gross examination. Figure 2. Histology, hematoxylin and eosin. A. Pulmonary thromboembolus at the bifurcation of the pulmonary arteries and pulmonary trunk. B. Hemorrhagic infarct and thromboemboli in varying stages of organization, right lower lobe, lung. C. Cross section of the proximal left anterior descending coronary artery with thromboembolus. D. Cross section of the posterior descending coronary artery with thromboembolus. Figure 2. Histology, hematoxylin and eosin. A. Pulmonary thromboembolus at the bifurcation of the pulmonary arteries and pulmonary trunk. B. Hemorrhagic infarct and thromboemboli in varying stages of organization, right lower lobe, lung. C. Cross section of the proximal left anterior descending coronary artery with thromboembolus. D. Cross section of the posterior descending coronary artery with thromboembolus. Figure 3. Patent foramen ovale, gross examination. Figure 3. Patent foramen ovale, gross examination. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

Kang, Hyun-Seung, Moon Hee Han, Bae Ju Kwon, Cheolkyu Jung, Jeong-Eun Kim, O.-Ki Kwon, and Chang Wan Oh. "Is Clopidogrel Premedication Useful to Reduce Thromboembolic Events During Coil Embolization for Unruptured Intracranial Aneurysms?" Neurosurgery 67, no. 5 (November 1, 2010): 1371–76. http://dx.doi.org/10.1227/neu.0b013e3181efe3ef.

Full text

Abstract:

Abstract BACKGROUND: Thromboembolism is a common complication related to coil embolization of intracranial aneurysms. OBJECTIVE: To identify factors related to thromboembolic events during coil embolization for unruptured intracranial aneurysms and to evaluate the role of clopidogrel premedication to prevent thromboembolisms. METHODS: Since March 2006, clopidogrel has been administered to patients with unruptured aneurysms before coil embolization (the clopidogrel group) in our institution. The clopidogrel group (416 patients with 485 aneurysms) and the historical control group (140 patients with 159 aneurysms who received no antiplatelet premedication) were compared to find the efficacy of clopidogrel premedication. Various factors, including age, sex, body weight, and medical history of hypertension, diabetes mellitus, hyperlipidemia, smoking, previous stroke, and heart disease, as well as clopidogrel premedication, were analyzed in relationship to the development of a procedure-related thromboembolism. RESULTS: Procedure-related thromboembolic events tended to occur less frequently in the clopidogrel group compared with the control group (7.4% vs 12.6%; P = .05), and clopidogrel premedication could modify the risk in female patients from 11.1% to 5.2% (P = .04). The use of multiple logistic regression analysis identified clopidogrel premedication (P = .03), smoking (P = .002), and hyperlipidemia (P = .02) as significant factors related to the formation of thromboembolism. CONCLUSION: Clopidogrel premedication seems to have a beneficial effect in reducing the number of procedure-related thromboembolisms during coil embolization for unruptured intracranial aneurysms, especially in female patients. Smoking and hyperlipidemia were independent risk factors related to thromboembolism.

APA, Harvard, Vancouver, ISO, and other styles

Bilge, Ayşegül, İsmail Karasoy, Elif Neziroğlu, and Yeşim Güner. "Upper extremity arterial thromboembolism in a patient with severe COVID-19 pneumonia: A case report." Joint Diseases and Related Surgery 32, no. 2 (June 11, 2021): 551–55. http://dx.doi.org/10.52312/jdrs.2021.82766.

Full text

Abstract:

Although novel coronavirus-2019 (COVID-19) primarily affects the respiratory system, it can affect multiple organ systems, leading to serious complications, such as acute respiratory distress syndrome (ARDS) and multiple organ failure. Nearly 20 to 55% of patients with COVID-19 experience coagulation disorders that cause high mortality in line with the severity of the clinical picture. Thromboembolism can be observed in both venous and arterial systems. The vast majority of thromboembolic events are associated with the venous system and are often observed as pulmonary embolism. Arterial thromboembolisms often involve the arteries in the lower extremities, followed by those in the upper extremities. Herein, we report a rare case of COVID-19 pneumonia whose left arm was amputated at the forearm level after arterial thromboembolism in the left upper extremity. This case report is valuable, as it is the first reported case of upper extremity arterial thromboembolism in Turkey, as well as the only case in the literature in which the patient underwent four surgical interventions and is still alive.

APA, Harvard, Vancouver, ISO, and other styles

Marinkovic, Jovana, and Olivera Tarabar. "Multiple myeloma and deep vein thrombosis/pulmonary thromboembolism - incidence and risk factors." Medical review 75, no. 7-8 (2022): 230–36. http://dx.doi.org/10.2298/mpns2208230m.

Full text

Abstract:

Introduction. Deep vein thrombosis and pulmonary thromboembolism are among the most important causes of morbidity and mortality in cancer patients. They are common and serious complications that are affected by various risk factors. The aim of this study was to determine the incidence of thromboembolic complications and their association with risk factors in patients with newly diagnosed multiple myeloma. Material and Methods. A retrospective study included 32 patients and the following variables were collected: age, C-reactive protein, beta-2 microglobulin, hemoglobin, platelets, total proteins, nephrotic syndrome, fibrinogen, D-dimer, albumin, lactate dehydrogenase, creatinine, calcium, gender, performance status, type of multiple myeloma, clinical stage, and applied therapy. All variables were compared between two groups of patients: group with thromboembolic complications (deep venous thrombosis and pulmonary thromboembolism), and the group without these complications. Results. The study sample included 18 men and 14 women. The patients? age ranged from 36 to 73 years. Of the 32 patients, 6 had deep venous thrombosis of the lower extremities, and 2 patients had deep venous thrombosis and pulmonary thromboembolism. The only two biomarkers that showed an association with venous thromboembolism in our patients with myeloma were elevated levels of C-reactive protein and D-dimer. Conclusion. The incidence of thromboembolic complications in patients with newly diagnosed multiple myeloma was 25%. When making the diagnosis of myeloma, risk factors that were significantly associated with venous thromboembolism were elevated levels of C-reactive protein and D-dimer. The occurrence of venous thromboembolism in patients with multiple myeloma was not associated with significantly higher mortality compared to patients without venous thromboembolism.

APA, Harvard, Vancouver, ISO, and other styles

Dávid, Marianna, Hajna Losonczy, Miklós Udvardy, Zoltán Boda, György Blaskó, Attila Tar, and György Pfliegler. "Risk assessment model for venous thromboembolism in hospitalized surgical and non-surgical patients in the 4th Hungarian Antithrombotic Guidelines entitled “Diminution and Treatment of Venous Thromboembolism”." Orvosi Hetilap 151, no. 34 (August 1, 2010): 1365–74. http://dx.doi.org/10.1556/oh.2010.28944.

Full text

Abstract:

A kórházban kezelt sebészeti és belgyógyászati betegekben jelentős a vénásthromboembolia-rizikó. Profilaxis nélkül, a műtét típusától függően, a sebészeti beavatkozások kapcsán a betegek 15–60%-ában alakul ki mélyvénás trombózis vagy tüdőembólia, és az utóbbi ma is vezető kórházi halálok. Bár a vénás thromboemboliát leggyakrabban a közelmúltban végzett műtéttel vagy traumával hozzák kapcsolatba, a szimptómás thromboemboliás események 50–70%-a és a fatális tüdőembóliák 70–80%-a nem a sebészeti betegekben alakul ki. Nemzetközi és hazai felmérések alapján a nagy kockázattal rendelkező sebészeti betegek többsége megkapja a szükséges trombózisprofilaxist. Azonban profilaxis nélkül marad a rizikóval rendelkező belgyógyászati betegek jelentős része, a konszenzuson alapuló nemzetközi és hazai irányelvi ajánlások ellenére. A belgyógyászati betegek körében növelni kell a profilaxisban részesülők arányát és el kell érni, hogy trombózisrizikó esetén a betegek megkapják a hatásos megelőzést. A beteg trombóziskockázatának felmérése fontos eszköze a vénás thromboembolia által veszélyeztetett betegek felderítésének, megkönnyíti a döntést a profilaxis elrendeléséről és javítja az irányelvi ajánlások betartását. A trombózisveszély megállapításakor, ha nem ellenjavallt, profilaxist kell alkalmazni. „A thromboemboliák kockázatának csökkentése és kezelése” című, 4. magyar antithromboticus irányelv felhívja a figyelmet a vénástrombózis-rizikó felmérésének szükségességére, és elsőként tartalmazza a kórházban fekvő belgyógyászati és sebészeti betegek kockázati kérdőívét. Ismertetjük a kockázatbecslő kérdőíveket és áttekintjük a kérdőívekben szereplő rizikófaktorokra vonatkozó bizonyítékokon alapuló adatokat.

APA, Harvard, Vancouver, ISO, and other styles

Pavelková, Eva. "Feline arterial thromboembolism." Companion Animal 24, no. 8 (September 2, 2019): 426–30. http://dx.doi.org/10.12968/coan.2019.0021.

Full text

Abstract:

Arterial thromboembolism is a common complication of feline cardiomyopathy. In many cats, underlying cardiac disease can be clinically silent. Risk factors for development of arterial thromboembolism include a previous episode of arterial thromboembolism; spontaneous echocardiographic contrast; severe left atrial enlargement; reduced left atrial and left ventricular function; and low left auricular appendage blood flow velocities. Diagnosis can be based on clinical signs, but echocardiography is necessary to confirm the presence of cardiomyopathy. Antithrombotic treatment is often empirical, as prospective studies are lacking. Clopidogrel has been shown to be superior to aspirin in prevention of subsequent arterial thromboembolism events, and future studies might show efficacy of other antithrombotic drugs. Cats that survive the initial thromboembolic event might have a fairly favourable prognosis, with a survival of over 12 months.

APA, Harvard, Vancouver, ISO, and other styles

Petrushenko, V. V., V. I. Voistryk, D. I. Grebeniuk, and O. V. Levadnyi. "The problem of prevalence, thromboprophylaxis and diagnostic strategies of thromboembolism in patients with COVID-19." Reports of Vinnytsia National Medical University 26, no. 3 (September 29, 2022): 491–96. http://dx.doi.org/10.31393/reports-vnmedical-2022-26(3)-25.

Full text

Abstract:

Annotation. Coronavirus infection is associated with a large number of complications, among which thromboembolisms of various localization are extremely serious. This article presents an overview of current literature data on the prevalence, need for thromboprophylaxis and strategic diagnostic goals in patients who have experienced thromboembolism of various vessels against the background of COVID-19. From the PubMed, ScienceDirect, UpToDate, Web of science, Scopus databases, 30 sources were selected and reviewed that met the query conditions: the most recent publications (over the last 5 years) or the latest publications on this issue (regardless of the age). Thromboembolic complications arising from COVID-19 correlate with increased disease severity and worsening of treatment outcomes. Patients with COVID-19 had a high risk of venous thromboembolic events (VTE) (a significant proportion is pulmonary embolism (PE) and deep vein thrombosis (DVT) of the lower extremities), in contrast to the heterogeneity of the development of arterial thromboembolic events (ATE) (low rates of development myocardial infarction and stroke). It is important to implement diagnostic and search strategies for early detection of thromboembolism in patients suffering from coronavirus infection. In addition, according to the opinion of most authors, the number of thromboembolic events decreases against the background of taking primary thromboprophylaxis, which is confirmed by a decrease in the percentage of thromboembolic complications in patients with a diagnosis of SARS-CoV-2 infection. Therefore, conducting a more skeptical assessment of the possibility of the development of VTE is important for the prevention of complications of the coronavirus infection. The study of these problems allows us to use the acquired knowledge on the development of thromboembolic events in patients against the background of the incidence of COVID-19 in a more detailed and justified manner and, accordingly, to improve the methods of diagnosis, treatment and prevention of these complications.

APA, Harvard, Vancouver, ISO, and other styles

Popov, S. V., R. G. Guseynov, I. N. Isakova-Sivak, K. V. Sivak, O. N. Skryabin, V. V. Perepelitsa, D. I. Sengirbaev, N. S. Bunenkov, P. G. Osipov, and T. A. Lelyavina. "Thromboembolic complications in urogenital cancers: incidence, risk factors and prevention." Cancer Urology 20, no. 1 (May 17, 2024): 164–73. http://dx.doi.org/10.17650/1726-9776-2024-20-1-164-173.

Full text

Abstract:

Numerous studies indicate a decrease in overall survival among cancer patients who have developed thromboembolic complications. The article presents a review of literature on thromboembolic complications in patients with kidney, bladder, and prostate cancer. The analysis of publications indicates a variety of risk factors and heterogeneous frequency of thromboembolism in patients with malignant neoplasms of the genitourinary system. Prevention of thromboembolism is carried out at all stages of treatment: outpatient, after surgery, during chemotherapy, but is accompanied by a fairly high risk of hemorrhagic complications and recurrences. Direct oral anticoagulants are an alternative to low-molecular-weight heparin for prevention of cancer-associated thromboembolism due to their convenience, efficacy and safety for most patients. An important task is to select patients for primary thromboprophylaxis based on stratification of the risk of thromboembolic complications using prognostic scales.

APA, Harvard, Vancouver, ISO, and other styles

Gala, Dhir, Taylor Newsome, Nicole Roberson, Soo Min Lee, Marvel Thekkanal, Mili Shah, Vikash Kumar, Praneeth Bandaru, and Vijay Gayam. "Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview." Diseases 10, no. 4 (September 30, 2022): 73. http://dx.doi.org/10.3390/diseases10040073.

Full text

Abstract:

Inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the intestines. The underlying inflammation activates the coagulation cascade leading to an increased risk of developing arterial and venous thromboembolic events such as deep vein thrombosis and pulmonary embolism. Patients with IBD are at a 2–3-fold increased risk of developing thromboembolism. This risk increases in patients with active IBD disease, flare-ups, surgery, steroid treatment, and hospitalization. These complications are associated with significant morbidity and mortality making them important in clinical practice. Clinicians should consider the increased risk of thromboembolic events in patients with IBD and manage them with appropriate prophylaxis based on the risk. In this review, we discuss the literature associated with the pathophysiology of thromboembolism in patients with IBD, summarize the studies describing the various thromboembolic events, and the management of thromboembolism in patients with IBD.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Thromboembolism"

Sáez, Giménez Berta. "Venous thromboembolism after lung transplantation." Doctoral thesis, Universitat Autònoma de Barcelona, 2018. http://hdl.handle.net/10803/666689.

Full text

Abstract:

La enfermedad tromboembólica es una complicación frecuente tras el trasplante de órgano sólido y, específicamente, tras el trasplante pulmonar. Los objetivos de nuestro trabajo fueron: describir los factores de riesgo de la enfermedad tromboembólica, evaluar el impacto de un protocolo de profilaxis extendido y describir los perfiles de coagulación antes y hasta 1 año tras el trasplante pulmonar. Con dicho objetivo llevamos a cabo dos estudios; el primero compara retrospectivamente una cohorte estudio (n=138) que recibió profilaxis con enoxaparina 90 días post-trasplante y una cohorte control histórica (n= 195) que recibió profilaxis únicamente durante el período de hospitalización post-trasplante. El segundo estudio, es un estudio prospectivo para describir el perfil de coagulación de 48 pacientes previamente al trasplante, en las primeras 24-72 horas post-trasplante, a las 2 semanas, 4 meses y 1 año post-trasplante. La incidencia de enfermedad tromboembólica en nuestra población fue del 15.3% (95% IC: 11.6-19.4). El tiempo medio del trasplante al evento fue de 40 (p25-75, 14-112) días. En este estudio, los factores de riesgo que se asociaron a la enfermedad tromboembólica fueron el género masculino y la enfermedad pulmonar intersticial difusa como enfermedad de base. La profilaxis extendida con enoxaparina no disminuyó la incidencia de enfermedad tromboembólica. En el estudio que describe los perfiles de coagulación transcurrido 1 año tras el trasplante pulmonar, encontramos que la mayor parte de marcadores de un estado procoagulante se normalizan a las 2 semanas del trasplante; sin embargo, al año todavía encontramos algunos pacientes niveles alterados de factor VIII y factor de Von Willebrand. Los pacientes que presentaron alguna complicación trombótica en los primeros 4 meses tras el trasplante, tenían niveles más elevados de factor VIII a las 2 semanas. Se necesitarán estudios multicéntricos con mayor tamaño muestral para poder diseñar estrategias profilácticas adecuadas.
Venous thromboembolism is a frequent complication after solid organ transplantation and, specifically, after lung transplantation. The objectives of this study were to describe risk factors for venous thromboembolism, to assess the impact of an extended prophylaxis protocol and to describe coagulation profiles before and up to 1 year after lung transplantation. We performed 2 studies. The first study compared a cohort (n=138) that received 90-day extended prophylaxis with enoxaparin and a historical control cohort (n= 195) that received prophylaxis only during post-transplant hospitalization. The second study is a prospective study to describe the coagulation profiles of 48 patients before lung transplantation and at 24- 72 hours, 2 weeks, 4 months and 1 year after lung transplantation. The cumulative incidence of venous thromboembolism was 15.3% (95% CI: 11.6-19.4). Median time from transplant to the event was 40 (p25-75, 14-112) days. In this study, the risk factors associated with venous thromboembolism were male gender and interstitial lung disease. Ninety-day extended prophylaxis did not reduce the incidence of VTE. In the second study to describe coagulation profiles up to 1 year after lung transplantation, we found that most markers of a procoagulant state normalize at 2 weeks after lung transplantation and that abnormal values of factor VIII and Von Willebrand factor persist at 1 year. Patients with venous thromboembolism at 4 months had higher values of factor VIII at 2 weeks. Larger, multicenter studies are needed to confirm these results and to design appropriate prophylactic strategies.

APA, Harvard, Vancouver, ISO, and other styles

Parkin, Lianne, and n/a. "Risk factors for venous thromboembolism." University of Otago. Dunedin School of Medicine, 2008. http://adt.otago.ac.nz./public/adt-NZDU20080513.145314.

Full text

Abstract:

Background: Many risk factors for venous thromboembolism have been identified, but two particular exposures - the use of combined oral contraceptives and long-distance air travel - have generated considerable concern in recent years. In contrast, a possible link between venous thromboembolism and a third exposure - the use of psychotropic drugs - was first raised in the 1950s, but has received surprisingly little attention. Information about all three exposures and the risk of fatal events is limited. These risks were examined in three inter-related national population-based studies. Methods: The underlying study population included all men and women aged 15 - 59 years who died in New Zealand between 1990 and 2000, for whom the underlying cause of death was pulmonary embolism. The potential associations between fatal pulmonary embolism and the use of oral contraceptives and psychotropic drugs were explored in a general practice records-based case-control study. Non-users were the reference category for all analyses. Contraceptive supply data were used to estimate the absolute risk of death from pulmonary embolism in users of oral contraceptives. A second case-control study, in which computer-assisted telephone interviews were undertaken with the next of kin of cases who had been resident in New Zealand, and with sex and age-matched controls randomly selected from the electoral roll, investigated the possible association between long-distance air travel and fatal pulmonary embolism. Finally, the absolute risk of dying from pulmonary embolism following a long-distance flight was estimated in a descriptive study based on official migration data and deaths in recent air travellers. Results: The adjusted odds ratio for use of any oral contraceptive in the three months before the index date (the onset of the fatal episode) was 13.1 (95% CI 4.4 - 39.0). The odds ratio for formulations containing desogestrel and gestodene was about three times higher than the point estimate for levonorgestrel products; preparations containing cyproterone acetate appeared to carry the highest risk. The estimated absolute risk of fatal pulmonary embolism in current users of oral contraceptives was 10.5 (95% CI 6.2 - 16.6) per million woman-years. The adjusted odds ratio for current use of any antipsychotic was 13.3 (95% CI 2.3 - 76.3). Low-potency antipsychotics carried a 20-fold increase in risk; thioridazine was the main drug involved. Antidepressant use was also associated with a significantly increased risk (adjusted odds ratio 4.9 [95% CI 1.1 - 22.5]). Compared with non-travellers, people who had undertaken a flight of more than eight hours� duration in the preceding four weeks were eight times more likely to die from pulmonary embolism (odds ratio 7.9 [95% CI 1.1 - 55.1]). The absolute risk of fatal pulmonary embolism following air travel of more than eight hours was 1.3 (95% CI 0.4 - 3.0) per million arrivals. Conclusions: The present research was the first to have estimated the relative risks of fatal pulmonary embolism in relation to three exposures: oral contraceptive use in a population in which preparations containing desogestrel and gestodene preparations were widely used, conventional antipsychotics, and long-distance air travel. The findings were consistent with previous, and subsequent, studies of non-fatal events. Increased risks of fatal pulmonary embolism in users of antidepressants, and in people with an intellectual disability, have not been described previously and warrant further investigation. Referral and diagnostic biases are very unlikely in these studies of fatal events, and other types of bias and possible confounding are considered unlikely explanations for the findings.

APA, Harvard, Vancouver, ISO, and other styles

Law, Wei-bong, and 羅緯邦. "The development of a clinical guideline on risk assessment and relatedpreventive measures of thromboembolism for adult surgical patients." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46582381.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kelly, James Anthony. "Venous thromboembolism after acute ischaemic stroke." Thesis, King's College London (University of London), 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.405599.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Chay, Wang George. "Thrombo-embolic complications and coagulation factor abnormalities in Chinese children after Fontan-type operation." Click to view the E-thesis via HKUTO, 2003. http://sunzi.lib.hku.hk/hkuto/record/B31971544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Hettiarachchi, Rohan Jagath Kumara. "Venous thromboembolism, cancer and low molecular weight heparin." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2000. http://dare.uva.nl/document/84386.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kraaijenhagen, Roderik A. "The etiology, diagnosis and treatment of venous thromboembolism." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2000. http://dare.uva.nl/document/84205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Chay, Wang George, and 蔡旺. "Thrombo-embolic complications and coagulation factor abnormalities in Chinese children after Fontan-type operation." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B31971544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Beutel, Bernhard. "Preventing venous thromboembolism at a district hospital : a quality improvement study." Thesis, Stellenbosch : Stellenbosch University, 2013. http://hdl.handle.net/10019.1/97180.

Full text

Abstract:

Thesis (MFamMed)--Stellenbosch University, 2013.
ENGLISH ABSTRACT: Background: Pulmonary embolism (PE) is the most common preventable cause of hospital deaths, and almost all hospitalised patients have at least one risk factor for venous thrombo-embolism (VTE). Despite the availability of highly effective thromboprophylaxis in prevent-ing VTE, numerous studies worldwide have demonstrated its under-utilization. The aim of this study was to review and improve the utilization of thromboprophylaxis in the prevention of VTE in hospitalized patients at Oudtshoorn district hospital. Method: A quality improvement cycle (QIC). Retrospective analysis of files of adult patients admitted to the male and female wards at Oudtshoorn district hospital was performed prior to and after a 5 month intervention phase. The target standards for the QIC were: 1) Availability of a written hospital policy on VTE prevention; 2) Every adult admission should have a for-mal VTE risk assessment documented; 3) Every adult admission who is at risk for VTE should receive thromboprophylaxis. Results: Thirty eight percent of adult patients admitted to Oudtshoorn hospital, excluding the maternity ward, were at risk of developing VTE. There was no written hospital policy on VTE prevention. This was developed and made available during the intervention. In the pre-intervention group there were no patients who had a documented VTE risk assessment. The post intervention group showed a considerable increase with 45.2% having had a completed VTE risk assessment on admission (p<0.00001). In the pre-intervention group only 4.6 per-cent of patients who were at risk of VTE received thromboprophylaxis. There was a statisti-cally significant difference in the number of patients at risk who received thromboprophylax-is in the post-intervention group where 36% of these patients received thromboprophylaxis (p<0.00001). Conclusions: The study identified a major shortcoming in the prevention of VTE in those patients at risk who were admitted to Oudtshoorn district hospital. An intervention as part of a quality improvement cycle has been able to demonstrate a significant improvement in the detection of patients who are at risk of VTE and a subsequent improvement in appropriate thromboprophylaxis. A number of barriers to their implementation have been identified and need to be addressed. This QIC may in time be of value to assist other district hospitals in addressing the issue of VTE prevention.
AFRIKAANSE OPSOMMING: No abstract available.

APA, Harvard, Vancouver, ISO, and other styles

Patel, Rajesh Kantilal. "Risk factors for venous thromboembolism in the black population." Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.416109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Thromboembolism"

Shirato, Kunio, ed. Venous Thromboembolism. Tokyo: Springer-Verlag, 2005. http://dx.doi.org/10.1007/b138641.

Full text

APA, Harvard, Vancouver, ISO, and other styles

F, Tapson Victor, ed. Venous thromboembolism. Philadelphia: Saunders, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

F, Tapson Victor, Fulkerson William J, and Saltzman Herbert A, eds. Venous thromboembolism. Philadelphia: Saunders, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Fulkerson, William J., and Herbert A. Saltzman. Venous thromboembolism. Philadelphia: Saunders, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

1932-, Dalen James E., ed. Venous thromboembolism. New York: Marcel Dekker, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Z, Goldhaber Samuel, and Ridker Paul M. 1959-, eds. Thrombosis and thromboembolism. New York: M. Dekker, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Thachil, Jecko, and Catherine Bagot, eds. Handbook of Venous Thromboembolism. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119095606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Piazza, Gregory, Benjamin Hohlfelder, and Samuel Z. Goldhaber. Handbook for Venous Thromboembolism. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20843-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Llau, Juan V., ed. Thromboembolism in Orthopedic Surgery. London: Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-4336-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Wille-Jørgensen, Peer. Prophylaxis of postoperative thromboembolism. København: Lægeforeningens, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Thromboembolism"

Heinzelmann, Michael, and Julia Fox. "Thromboembolism." In General Trauma Care and Related Aspects, 177–201. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-88124-7_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Becker, Daniel M. "Thromboembolism." In Prevention in Clinical Practice, 201–18. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5356-0_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Foord, Aimee, and Arash Mahajerin. "Thromboembolism." In Benign Hematologic Disorders in Children, 269–94. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-49980-8_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Phelan, Herb A. "Thromboembolism." In Surgical Critical Care and Emergency Surgery, 199–208. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119317913.ch21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Peaceman, Alan. "Thromboembolism." In Protocols for High-Risk Pregnancies, 210–15. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444323870.ch25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Rozanski, Elizabeth. "Thromboembolism." In Critical Care, 110–11. New York: Routledge, 2021. http://dx.doi.org/10.1201/9781315140629-59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Khalil, Asma, Louise Bowles, Patrick O’Brien, and Hannah Cohen. "Systemic Thromboembolism in Pregnancy: Venous Thromboembolism." In Disorders of Thrombosis and Hemostasis in Pregnancy, 81–104. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-15120-5_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Khalil, Asma, Louise Bowles, and Pat O’Brien. "Systemic Thromboembolism in Pregnancy: Venous Thromboembolism." In Disorders of Thrombosis and Hemostasis in Pregnancy, 51–69. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-4411-3_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Gibbs, Lawrence, Josiah Moulton, and Vincent Tichenor. "Venous Thromboembolism." In Family Medicine, 1041–50. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-04414-9_88.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Phelan, Herb A., and Scott H. Norwood. "Venous Thromboembolism." In Surgical Critical Care and Emergency Surgery, 192–201. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9781118274231.ch20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Thromboembolism"

Panzer, S., I. Pabinger, R. Dudczak, E. Schulz, E. Wurz, K. Lechner, and K. Lechner. "PROTEIN S AND ANTICARDIOLIPIN ANTIBODIES IN PATIENTS WITH LUPUS ANTICOAGULANT WITH OR WITHOUT THROMBOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644236.

Full text

Abstract:

Arterial and venous thrombosis frequently occur in patients with lupus anticoagulant. We investigated in patients with lupus anticoagulant the possible association between protein S:Ag deficiency and/or anticardiolipin antibodies and a history of thrombosis. In 27 patients (8 with and 19 without a history of thromboembolic disease) free protein S:Ag was determined with immunoelectrophoresis in PEG 8000 precipitated plasma. Anticardiolipin antibodies were measured in 22 patients (10 with thromboembolism) by means of a solid phase radioimmunoassay.Free plasma protein S:Ag was normal or elevated in 25 patients and slightly decreased (protein S:Ag 67%) in 2 patients without thromboembolism. 2-dimensional electrophoresis revealed a normal distribution of the free and of the complexed form of protein S:Ag. Anticardiolipin antibodies were found in 6 out of 10 patients with a history of thrombosis (5 of 7 with venous thrombosis, 1 of 1 with cerebral infarction , none of 2 with combined venous and arterial thromboembolism) and in 4 out of 12 patients without a history of thrombosis.We conclude 1. the thrombophilic state in patients with lupus anticoagulant cannot be explained by a reduction of protein S:Ag, and 2. there seems to be no correlation between the presence or absence of anticardiolipin antibodies and the development of thromboembolic disease.

APA, Harvard, Vancouver, ISO, and other styles

Lowe, O. DG. "RHEOLOGY AND VENOUS THROMBOEMBOLISM." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643990.

Full text

Abstract:

Changes in the composition of the blood, venous stasis, and interaction of the blood with the vessel wall (Virchow's triad) all have rheological aspects which may promote venous thrombogenesis.Blood composition and rheology. Increasing levels of venous haematocrit and fibrinogen increase bulk blood viscosity, especially at low shear rates such as are encountered in veins, when red cell aggregation occurs. Static blood requires a minimum shear stress for flow (yield stress), which is also strongly dependent on haematocrit and fibrinogen levels. Increases in haematocrit and fibrinogen also promote platelet adhesion and aggregation. Polycythaemia carries an increased risk of venous thromboembolism, which can be reduced by lowering the haematocrit; conversely, anaemic patients (renal failure, pernicious anaemia) have a subnormal prevalence of pulmonary embolism at autopsy. Increased preoperative levels of haematocrit, fibrinogen and blood viscosity predicted postoperative deep vein thrombosis in some studies, but not in others: they have complex relationships to other risk factors and illnesses. Postoperative changes in haematocrit, fibrinogen and blood viscosity may also be relevant to thrombogenesis, as may haemoconcentration in leg veins.Venous flow disturbance and rheology. The flow behaviour of particles and cells in venous valve pockets has been studied by Karino: particles and cells were observed to leave mainstream flow and circulate in paired vortices in low-shear areas within the valve pockets. A cell-poor hypoxic area at the apex of the valve pocket may favour thrombogenesis. Valve pockets might therefore act as in vivo aggregometers, with optimal conditions for activated cells or coagulation products to promote platelet and red cell aggregation, which might be facilitated by increases in haematocrit or fibrinogen. Sevitt has observed cellular aggregates in valve pockets at autopsy, which might act as a nidus for thrombus initiation. Successive layers of thrombus will disturb flow steamlines, as well as generating procoagulant activity: hence a series of "aggregometers" might result in successive bursts of thrombosis and the layered structure of venous thrombi observed by Sevitt. Variations in haematocrit, fibrinogen and red cell aggregation may influence stasis of blood following venous occlusion by thrombus, and hence affect thrombotic extension; they may also influence residual lung perfusion following pulmonary embolism.Therapeutic aspects of rheology. Leg stockings and other physical methods of preventing deep vein thrombosis may improve flow disturbance in valve pockets, as well as in axial veins. The efficacy of perioperative dextran in prevention of venous thromboembolism may partly reflect haemodilution and its rheological consequences. Likewise, postoperative defibrination with ancrod reduced the incidence and extent of deep vein thrombosis after hip surgery, which may partly reflect reductions in plasma viscosity and red cell aggregation. Defibrination with ancrod reduced the haemodynamic disturbance, and the mortality, of experimental pulmonary embolism in dogs, possibly by increasing residual perfusion.. Similarly, improved perfusion after thrombolytic therapy of pulmonary embolism in man may reflect the rheological consequences of fibrinogen depletion, as well as thrombolysis.

APA, Harvard, Vancouver, ISO, and other styles

Ali, Noor-E.-Seher, Jennifer Alyono, Yohan Song, Ali Kouhi, and Nikolas Blevins. "Postoperative Venous Thromboembolism after Neurotologic Surgery." In 29th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679623.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Brzoska, T., R. Vats, M. F. Bennewitz, E. Tutuncuoglu, S. C. Watkins, M. V. Ragni, M. D. Neal, M. T. Gladwin, and P. Sundd. "Platelet αIIbβ3 Promotes Acute Pulmonary Thromboembolism." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2404.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Boda, Z., G. Pfliegler, I. Tornai, M. Udvardy, J. Hársfalvi, and K. Rak. "LONG-TERM COUMAROL PLUS SMALL DOSE ASA THERAPY IN PATIENTS WITH PROSTHETIC HEART VALVE. SOME QUESTIONS OF LABORATORY CONTROL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643268.

Full text

Abstract:

Thromboembolism in patients with prosthetic heart valves remains a major time-related problem (Sullivan 1971, Dale 1976, Chesebro 1983). Patients receiving anticoagulant plus antiplatelet agent have the lowest incidence of thromboembolism but the risk of bleeding is not negligible. The laboratory control of combined therapy is unsolved.This study considers the thromboembolic prophylaxis of 38 patients with prosthetic heart valve. Cou-marol treatment was combined with ASA (1 000 mg/week, 36 months follow up).Prothrombin ratio was used in control of the oral anticoagulant therapy. Malondialdehyde production was measured parallel with the so-called malondialdehyde-ratio (MDA-ratio = malondialdehyde level of patient/ control plasma). MDA-ratio, platelet aggregation, thromboxane and prostacycline metabolites were studied 48 hours after 500 mg ASA intake. The average of MDA-ratio was 0.42 ± 0.23 (from 137 measurements). The therapeutic range of MDA-ratio is 0.7 - 0.2. Value below 0.2 means overdosed, over 0.7 means an ineffective ASA therapy. Normal first and second phase platelet aggregation was observed in 23 % of cases when MDA-ratio was below 0.5. Only in 4 % of patients with MDA-ratio over 0.7 was found an abnormal platelet aggregation. The mean prothrombin ratio was 1.59 ± 0.22.No gastrointestinal bleeding or thromboembolism was observed during the 36 months follow up. Contrary to the literary data (Chesebro 1983) coumarol plus small dose ASA did not result excessive bleeding and can be suggested for patients with prosthetic heart valve. Examination of both the prothrombin and the malondialdehyde ratio with study of platelet aggregation is recommended as laboratory control.

APA, Harvard, Vancouver, ISO, and other styles

Borisov, V., M. Platunova, V. Abramov, and M. Kaplunova. "Venous Thromboembolism Risks Modeling in Burn Patients." In 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Garcia-Ortega, Alberto, Enrique Zaldivar, Raquel Lopez-Reyes, Dolores Nauffal, and Manuel Monreal. "Venous thromboembolism in patients immobilized at home." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Lowe, G. D. O. "EPIDEMIOLOGY AND RISK PREDICTION OF VENOUS THROMBOEMBOLISM." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642965.

Full text

Abstract:

Uses of epidemiology. Venous thromboembolism continues to be an important cause of death and disability in Western Countries. Its epidemiology may provide clues to etiology, e.g. the increased incidence in oral contraceptive users, and the low prevalence at autopsy in Central Africa or Japan compared to the U.S.A. A second use is the monitoring of time-trends: the diagnosis of pulmonary embolism increased during the 1970s, although the case fatality decreased. A third use is the identification and quantification of risk factors: these could be modified in the hope of prevention, or else used to select high risk groups for selective prophylaxis, e.g. during acute illness. Prevention is the only feasible approach to reducing the burden of venous thromboembolism, since most cases are not diagnosed, and since the value of current treatment is debatable.Case definition. Presents problems: clinical diagnosis is unreliable, and should if possible be supported by objective methods. Autopsy studies are performed on selected populations, at a decreasing rate; the frequency of thromboembolism depends on technique; and pathologists cannot be blinded and are open to bias. It can also be difficult to judge whether a patient dying with pulmonary embolism died from pulmonary embolism. 125I-fibrinogen scans indicate minimal disease, and now present ethical problems in screening due to risks of viral transmission. Venography is invasive and is not readily repeatable, which limits its use as a screening method. Plethysmography merits wider evaluation, since it is non-invasive, and sensitive to major thrombosis.Community epidemiology. Data on the community epidemiology are limited. The risk increases with age. When age is taken into account, there is little sex difference. Overweight in women, use of oral contraceptives and blood group A increase the risk: smoking, varicose veins, blood pressure, cholesterol and glucose do not, on current evidence. Long-term follow-up of patients with proven thromboembolism shows an increased risk of malignancy, hence occult cancer may also be a risk factor. Polycythaemia and certain congenital deficiencies (e.g. antithrombin III) are also well-recognised risk factors, although uncommon.Hospital epidemiology. Data on hospital epidemiology are derived largely from autopsy prevalence, and from short-term incidence of minimal thrombosis detected by 125I—fibrinogen scanning. Old, immobile and traumatised patients are most at risk. Previous thromboembolism, polycythaemia, antithrombin III deficiency, hip and leg fractures, elective hip and leg surgery, hemiplegia, paraplegia, and heart failure carry high risks, and merit consideration for routine prophylaxis. The risk in elective surgery precedes the operation, and increases with age, overweight, malignancy, varicose veins, non-smoking, and operative factors (duration, approach, general anaesthesia, intravenous fluids). Diabetics appear to have no extra risk. Combinations of clinical variables can be used to predict high risk groups for selective prophylaxis, but combination indices require further study. Laboratory variables may increase the predictability of deep vein thrombosis, but the results of published studies are conflicting, and the cost-effectiveness of laboratory prediction should be evaluated.

APA, Harvard, Vancouver, ISO, and other styles

Celik, Gokhan, Aydin Ciledag, Cabir Yuksel, Bulent M. Yenigun, Hakan Kutlay, Levent Yazicioglu, Sibel Percinel, and Akin Kaya. "Pulmonary Artery Intimal Sarcoma Mimicking Pulmonary Thromboembolism." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3441.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kohli, A., J. Fagg, S. Sompalli, and O. Abdulfattah. "Tetrahydrocannabinol Induced Venous Thromboembolism: Myth or Reality." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5426.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Thromboembolism"

Lurie, Fedor, and Fausto Passariello. Risk Assessment in Venous ThromboEmbolism. Fondazione Vasculab, January 2016. http://dx.doi.org/10.24019/2016.vte_risk.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Balk, M.D., M.P.H., Ethan M., Alexandra G. Ellis, M.Sc., Mengyang Di, M.D., Ph.D., Gaelen P. Adam, M.L.I.S., and Thomas A. Trikalinos, M.D., Ph.D. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update. Agency for Healthcare Research and Quality (AHRQ), June 2017. http://dx.doi.org/10.23970/ahrqepccer191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

hou, xianbing, dandan chen, tongfei cheng, dan wang, xiaojun dai, yao wang, bixian cui, et al. Bleeding risk of anticoagulant therapy in patients with advanced cancer in palliative care settings：a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0064.

Full text

Abstract:

Review question / Objective: The systematic review aim to provide synthesised and appraised evidence to assess the bleeding risk of anticoagulant therapy in patients with advanced cancer in palliative care settings. Condition being studied: Cancer is a recognized risk factor for venous thromboembolism (VTE). The main forms of thromboembolic disease include pulmonary embolism (PE) and deep vein thrombosis (DVT). Given their diagnosis and often poor physical status, patients with advanced cancer are at particularly high risk of developing VTE, resulting in reduced activity levels or even immobility. The exact incidence and prevalence of VTE in the population of cancer patients receiving hospice or palliative care has not been well investigated and few reports are available. Clinical studies have not yet determined whether such patients benefit from anticoagulant therapy and whether there is an increased risk of bleeding and death.

APA, Harvard, Vancouver, ISO, and other styles

Zhao, Chenxi, Jiannan Yao, and Yang Ge. Risk factors of venous thromboembolism in lung cancer patients: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Hamilton, Michael T. Case Study: The Venous Thromboembolism Collaborative Team at the Johns Hopkins Hospital. Fort Belvoir, VA: Defense Technical Information Center, May 2009. http://dx.doi.org/10.21236/ada516530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Chen, Wen-Tien. Control of Venous Thromboembolism and Metastasis in Breast Cancer by Antifibrinolysis Mechanism. Fort Belvoir, VA: Defense Technical Information Center, September 2009. http://dx.doi.org/10.21236/ada586814.

Full text

APA, Harvard, Vancouver, ISO, and other styles

A, Bengolea, Chamorro F, Ozon N, Catalano HN, and Izcovich A. Effectiveness and safety of utilizing imaging techniques to guide treatment in patients with venous thromboembolism. Epistemonikos Interactive Evidence Synthesis, January 2023. http://dx.doi.org/10.30846/ies.2b03926263.v1.

Full text

Abstract:

Objective The objective of this systematic review is to perform a comprehensive evaluation of the efficacy and safety of the use of imaging to determine the duration of anticoagulant treatment in patients with thrombosis of any cause (idiopathic, resolved secondary or chronic) who have completed a period of 3 to 6 months of oral anticoagulant treatment. Methods In order to identify randomized clinical trials that evaluate our question of interest, we performed exhaustive searches in Epistemonikos and PubMed, from the date of creation of each source until February 2024. Additionally, we considered additional sources to identify trials that may not have been identified through electronic search. Two reviewers independently selected included studies, extracted data, and assessed risk of bias. We performed a quantitative synthesis (meta-analysis) and prepared summary tables of findings as recommended by the GRADE group. The results of this review were presented to a team of clinical experts from the medical clinic service of the German Hospital of Buenos Aires, who analyzed and made judgments for each of the proposed criteria within the framework of the evidence for the decision. After making judgments for each criterion, the experts formulated the clinical recommendation for the problem of interest. Result Through the search strategy, 514 references were identified and examined by title and abstract. Of these, 17 references were included for full-text evaluation. Finally, 2 randomized clinical trials were included. The evidence on the use of CT or venous Doppler to determine the duration of anticoagulation in patients with thromboembolic events of any type is very uncertain. The evidence on the use of tomography or venous Doppler to determine the duration of anticoagulation in patients with idiopathic thromboembolic events secondary to transient and/or chronic risk factors (patients with cancer) is very uncertain. Clinical recommendation The medical clinic service of the German Hospital [link_recommendation|recommendation](does not recommend using image-guided strategies to suspend anticoagulant treatment in patients with thromboembolisms) (CONDITIONAL RECOMMENDATION AGAINST, VERY LOW CERTAINTY IN THE EVIDENCE). Conclusions In this systematic review, we explored the usefulness of using imaging (tomography or venous Doppler) to determine the continuity of treatment with oral anticoagulants in patients with venous thrombosis. However, the evidence derived from the included studies has very low certainty.

APA, Harvard, Vancouver, ISO, and other styles

A, Bengolea, Chamorro F, Ozon N, Catalano HN, and Izcovich A. Effectiveness and safety of utilizing imaging techniques to guide treatment in patients with venous thromboembolism. Epistemonikos Interactive Evidence Synthesis, April 2024. http://dx.doi.org/10.30846/ies.2b03926263.

Full text

Abstract:

APA, Harvard, Vancouver, ISO, and other styles

Chen, Wen-Tien. Control of Venous Thromboembolism and Metastasis in Breast Cancer by Anti-Fibrinolysis Mechanism. Fort Belvoir, VA: Defense Technical Information Center, November 2010. http://dx.doi.org/10.21236/ada610996.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Haut, Elliott, Brandyn Lau, Deborah Hobson, Dauryne Shaffer, Peggy Kraus, Jonathan Aboagye, Norma Farrow, et al. Preventing Venous Thromboembolism: Empowering Patients and Enabling Patient-Centered Care via Health Information Technology. Patient-Centered Outcomes Research Institute (PCORI), November 2018. http://dx.doi.org/10.25302/11.2018.ce.12114489.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

Contents

Academic literature on the topic 'Thromboembolism'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Journal articles on the topic "Thromboembolism"

Dissertations / Theses on the topic "Thromboembolism"

Books on the topic "Thromboembolism"

Book chapters on the topic "Thromboembolism"

Conference papers on the topic "Thromboembolism"

Reports on the topic "Thromboembolism"